Deadline: Pfizer: Interventional Research Studies with Elranatamab
Projects that will be considered for Pfizer support will focus on generating evidence on priority gaps in the use of elranatamab in multiple myeloma across lines of treatment. The general areas of interest for this request include:
- Frontline use of elranatamab in newly diagnosed multiple myeloma, including sequencing with autologous Stem-Cell Transplant (ASCT)/Chimeric Antigen Receptor T-cells (CAR-T), focus on subpopulations of unmet needs, segmentation based on disease biology
- Optimal administration of elranatamab treatment in patient subpopulations based on patients (e.g. age/fitness/comorbidities), risk (e.g. HRCA, extramedullary disease, high tumor burden) and response characteristics
- Characterization, monitoring, and mitigation strategies of: Infections, CRS, Neurotoxicity/ ICANS, viral reactivation (incl. observing and monitoring emerging infections), other adverse events of elranatamab treatment
- Investigation and intervention of resistance/relapse mechanisms to elranatamab treatment, with focus on strategies to mitigate T-cell exhaustion and its clinical outcomes
- Retreatment-rechallenging strategies
Full details can be found here.
Contact Details
Internal: ird@dal.ca
External: Jacqueline Waldrop (Jacqueline.Waldrop@pfizer.com), with the subject line “RFP – Interventional Research Studies with Elranatamab June 2024.”
Deadlines
Internal: July 4, 2024 at 4:30pm.
External: July 18, 2024 at 11:59pm EST
The grants facilitator for your faculty can be found on the staff contact page. For additional resources, click here for guidance on internal deadlines and submission processes.
Time
Additional Dates/Times